REPORT DESCRIPTION INTRODUCTION

• Causes & Symptoms

• Diagnosis

• Unmet needs

• Current therapies

HOT TARGETS, MECHANISMS & THERAPIES

• Novel Disease mechanisms & therapies

• Leading & hot targets of NASH

• Novel targets of NASH

• NASH biomarkers • Genes involved in NASH

MARKET DATA

• Forecasting model

• Market dynamics

• Market sizing

• NASH Deals

PIPELINE ANALYSIS

• Development stage

• Leading players

• Therapeutic segmentation

• Target analysis

• Innovative approaches

Small molecules

• Pipeline

• Competitive landscape Large molecules

• Competitive landscape RNA-BASED THERAPY

• Pipeline

• Competitive landscape RECOMBINANT PROTEINS

• Pipeline

• Competitive landscape ANTIBODIES

• Pipeline

• Competitive landscape LARGE MOLECULES (UNSPECIFIED)

• Pipeline

OTHER MOLECULES

• Pipeline

NASH DRUG ANALYSIS BASED ON MECHANISM

MAJOR PLAYERS

• Company Profiles

• Overview, Pipeline & Deals

REFERENCE

“Nonalcoholicsteatohepatitis(NASH)PipelineAnalysis”givescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.Thereportcoversallthedrugsbeingdevelopedinvariousphases(Discovery,Preclinical&Clinicaldevelopment).Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNA-basedtherapeutics,butexcludesOff-label,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitis(NASH)Drugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministration(FDA)andthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliver-destroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceutical&biotechcompanies.AssomeofthecandidatesarenearingkeyR&Dmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead’sacquisitionofPhenexFXRprogram&Boehringer’sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnon-invasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNA-basedtherapies&Recombinantproteins.ThesemodalitiesmayprovideAnti-fibrosis,Anti-inflammatoryandmetabolicbenefits.